keyword
MENU ▼
Read by QxMD icon Read
search

paliperidone

keyword
https://www.readbyqxmd.com/read/29350127/converting-oral-to-long-acting-injectable-antipsychotics-a-guide-for-the-perplexed
#1
Jonathan M Meyer
There has been increasing recognition that antipsychotic nonadherence is common across all stages of schizophrenia, starting from the first episode. Moreover, numerous meta-analyses of the existing literature indicate superiority of long-acting injectable (LAI) over oral antipsychotics when one adjusts for the greater illness severity and duration among patients in LAI antipsychotic trials. The increasing availability of LAI antipsychotic options has raised interest in converting patients from oral medication; however, the successful transition from oral to the comparable LAI antipsychotic requires an understanding of the current extent of antipsychotic exposure, the kinetics of the LAI preparation, and the expected plasma levels achieved by the LAI formulation...
December 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29338294/the-importance-of-clinical-observation-a-case-of-subtle-tardive-dyskinesia-with-paliperidone-palmitate
#2
Hisham Mrb Omer, Andrew D Thompson
No abstract text is available yet for this article.
January 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29278968/clinical-improvement-relapse-and-treatment-adherence-with-paliperidone-palmitate-1-month-formulation-1-year-treatment-in-a-naturalistic-outpatient-setting
#3
Rosaria Di Lorenzo, Michela Cameli, Chiara Piemonte, Marisa Bolondi, Giulia Landi, Gabriella Pollutri, Ludovica Spattini, Valentina Moretti, Paola Ferri
PURPOSE: To evaluate paliperidone palmitate 1-month formulation (PP1M) effectiveness in a naturalistic outpatient psychiatric setting. MATERIALS AND METHODS: We collected data from 50 outpatients affected by schizophrenia disorders treated with PP1M for 12 months in an Italian Mental Health Department. After analyzing selected demographic, clinical and pharmacological variables, we performed mirror analysis to compare psychiatric hospitalizations and urgent consultations required by the same patient 6 and 12 months before and after PP1M implementation (primary outcome)...
December 27, 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/29278206/a-systematic-review-of-evidence-based-treatment-strategies-for-obsessive-compulsive-disorder-resistant-to-first-line-pharmacotherapy
#4
Umberto Albert, Donatella Marazziti, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Maina
BACKGROUND: Serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy (CBT) are first-line treatments for obsessive-compulsive disorder (OCD). However, a significant proportion of patients do not respond satisfactorily to first-choice treatments. Several options have been investigated for the management of resistant patients. OBJECTIVE: The aim of the present paper is to systematically review the available literature concerning the strategies for the treatment of resistant adult patients with OCD...
December 22, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29276595/one-patient-with-schizophrenia-showed-reduced-drug-induced-extrapyramidal-symptoms-as-a-result-of-an-alternative-regimen-of-treatment-with-paliperidone-3-and-6-mg-every-other-day
#5
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami
Background: Schizophrenia is a chronic disease that requires long-term management with antipsychotics. Antipsychotic drugs are given by tapering their dose, extending the dosing interval, and so on, as part of a treatment strategy to minimize the adverse effects while at the same time maintaining efficacy. Methods: We report the case of one patient with schizophrenia in whom the clinical symptoms were alleviated after treatment with 6 mg paliperidone. However, the patient developed extrapyramidal syndrome, for which 3 and 6 mg paliperidone were administered alternately every other day...
2017: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/29274734/antipsychotics-and-mortality-in-a-nationwide-cohort-of-29-823-patients-with-schizophrenia
#6
Heidi Taipale, Ellenor Mittendorfer-Rutz, Kristina Alexanderson, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Jari Tiihonen
INTRODUCTION: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration. METHODS: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64years with schizophrenia in Sweden (N=29,823 in total; N=4603 in the incident cohort)...
December 20, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29238631/ethnic-and-age-disparities-in-patients-taking-long-acting-injectable-atypical-antipsychotics
#7
Mateen Soleman, Nikki Lam, Benjamin K Woo
Introduction This study will determine whether different ethnicities and different age groups receive equal amounts of long-acting atypical antipsychotics in comparison to their oral equivalents. Methods Secondary analyses of data from the Los Angeles County Department of Health Services Electronic Health Record (total N=63,134 inpatient visits) were performed. Chi-squared statistics were used to compare ethnicity and age with the use of either risperidone injectable or paliperidone palmitate (r-LAIs) versus risperidone oral...
October 12, 2017: Curēus
https://www.readbyqxmd.com/read/29232310/comparison-of-paliperidone-palmitate-and-risperidone-long-acting-injection-in-schizophrenic-patients-results-from-a-multicenter-retrospective-cohort-study-in-france
#8
Frédéric Limosin, Drifa Belhadi, Denis Comet, Maud Pacou, Sophie Bouju, Kristel Van Impe, Pascal Guillon
PURPOSE/BACKGROUND: The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. METHODS: We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29226628/modeling-of-prolactin-response-following-dopamine-d2-receptor-antagonists-in-rats-can-it-be-translated-to-clinical-dosing
#9
Amit Taneja, An Vermeulen, Dymphy R H Huntjens, Meindert Danhof, Elizabeth C M De Lange, Johannes H Proost
Prolactin release is a side effect of antipsychotic therapy with dopamine antagonists, observed in rats as well as humans. We examined whether two semimechanistic models could describe prolactin response in rats and subsequently be translated to predict pituitary dopamine D2 receptor occupancy and plasma prolactin concentrations in humans following administration of paliperidone or remoxipride. Data on male Wistar rats receiving single or multiple doses of risperidone, paliperidone, or remoxipride was described by two semimechanistic models, the precursor pool model and the agonist-antagonist interaction model...
December 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/29161951/an-open-treatment-six-week-study-of-the-clinical-effectiveness-of-paliperidone-palmitate-in-schizophrenia-data-from-acute-units-in-spain-shadow-study
#10
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera, Marta García Dorado
OBJECTIVES: To evaluate clinical evolution of patients with schizophrenia admitted in acute units because of a relapse and treated with once-monthly Paliperidone Palmitate (PP1M). METHODS: This multicentre, open-label, prospective observational study followed patients with schizophrenia treated with PP1M in acute psychiatric units for up to 6 weeks. RESULTS: Out of the 280 enrolled patients, 61 received PP1M as antipsychotic monotherapy, and 219 in combination with other antipsychotics...
November 21, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/29158676/role-of-3-monthly-long-acting-injectable-paliperidone-in-the-maintenance-of-schizophrenia
#11
REVIEW
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca
Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participate in PP3M clinical trials; 3) to examine ethical implications, pros and cons of PP3M use and 4) to propose study designs to further assess PP3M...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29155881/correction-relationship-between-response-to-aripiprazole-once-monthly-and-paliperidone-palmitate-on-work-readiness-and-functioning-in-schizophrenia-a-post-hoc-analysis-of-the-qualify-study
#12
https://www.readbyqxmd.com/read/29141463/once-monthly-injection-of-paliperidone-palmitate-in-patients-with-recently-diagnosed-and-chronic-schizophrenia-a-post-hoc-comparison-of-efficacy-and-safety
#13
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan, Yu Feng
BACKGROUND: The use of long-acting injectable antipsychotics in recently diagnosed schizophrenia remains less explored. We evaluated the efficacy and safety of paliperidone palmitate once-monthly (PP1M) treatment in adult patients with recently diagnosed vs. chronic schizophrenia. RESEARCH DESIGN AND METHODS: These post-hoc analyses included two multicenter studies. Study 1 (NCT01527305) enrolled recently diagnosed (≤5 years) and chronic (>5 years) patients; Study 2 (NCT01051531) enrolled recently diagnosed patients only...
November 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29138607/evaluation-of-sleep-profile-in-schizophrenia-patients-treated-with-extended-release-paliperidone-an-open-label-prospective-study-in-southeast-asia
#14
Ronnachai Kongsakon, Nuntika Thavichachart, Ka Fai Chung, Leslie Lim, Beverly Azucena, Elizabeth Rondain, Benson Go, Fe Costales, Osot Nerapusee
Objective: To evaluate the effect of 6 months of treatment with paliperidone extended-release (ER) tablets on the sleep profile of patients with schizophrenia. Methods: A total of 984 patients meeting the The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia who switched their antipsychotic to paliperidone ER were recruited from 61 sites in five countries in Southeast Asia. We recorded patient demographics and assessed sleep quality and daytime drowsiness using visual analog scales...
2017: Psychology Research and Behavior Management
https://www.readbyqxmd.com/read/29101715/paliperidone-palmitate-improves-and-maintains-functioning-in-asia-pacific-patients-with-schizophrenia
#15
Hongyan Zhang, Ibrahim Turkoz, Jianmin Zhuo, Maju Mathews, Wilson Tan, Yu Feng
INTRODUCTION: Post hoc analyses (two single-arm studies) were conducted to determine the impact of once-monthly injection of paliperidone palmitate on functioning in adult patients with schizophrenia in the Asia-Pacific region. METHODS: Study 1 enrolled hospitalized patients with acute exacerbation of schizophrenia, and study 2 enrolled patients with recently diagnosed schizophrenia unsatisfactorily treated with oral antipsychotics. Patients received paliperidone palmitate, 150 mg eq...
November 3, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29097257/a-randomized-13-week-study-assessing-the-efficacy-and-metabolic-effects-of-paliperidone-palmitate-injection-and-olanzapine-in-first-episode-schizophrenia-patients
#16
Manli Huang, Liang Yu, Fen Pan, Shaojia Lu, Shaohua Hu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Hongli Qi, Yi Xu
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS: Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal...
October 31, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29077621/a-systematic-review-of-atypical-antipsychotics-in-chronic-pain-management-olanzapine-demonstrates-potential-in-central-sensitization-fibromyalgia-and-headache-migraine
#17
Xavier F Jimenez, Tharani Sundararajan, Edward C Covington
INTRODUCTION: Many psychopharmacologic agents are used as primary or adjunct agents in pain management. Atypical antipsychotics (AAs) have also been used as adjuncts in pain management regimens in a variety of manners; however, their efficacy in this capacity is unclear. METHODS: A systematic review of all studies examining AA use for pain was conducted. Three literature databases were utilized to search for word combinations of "pain" and a variety of commonly-prescribed AAs (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine, paliperidone, iloperidone, lurasidone)...
October 26, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/29048190/the-efficacy-and-tolerability-of-paliperidone-in-mania-of-bipolar-disorder-a-preliminary-meta-analysis
#18
Han-Yung Chang, Ping-Tao Tseng, Brendon Stubbs, Che-Sheng Chu, Dian-Jeng Li, Michele Fornaro, Andre Carvalho, Marco Solmi, Nicola Veronese, Eduard Vieta, Tien-Yu Chen, Yen-Wen Chen, Pao-Yen Lin, Philip Chik-Keung Chow
Paliperidone may be effective for the treatment of bipolar disorder (BD); however, the evidence has been mixed. This is the first meta-analysis to evaluate the efficacy, safety, and tolerability of paliperidone for the treatment of BD. We performed a systematic search of the literature using major electronic databases from inception to January 27, 2017. Randomized control trials (RCTs) investigating paliperidone treatment among patients with BD versus a placebo or other second-generation antipsychotics were included...
October 2017: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29047368/comparison-and-predictors-of-treatment-adherence-and-remission-among-patients-with-schizophrenia-treated-with-paliperidone-palmitate-or-atypical-oral-antipsychotics-in-community-behavioral-health-organizations
#19
Jeffrey P Anderson, Zeynep Icten, Veronica Alas, Carmela Benson, Kruti Joshi
BACKGROUND: Nonadherence to antipsychotic treatment increases the likelihood of relapse and progressive symptomatology in patients with schizophrenia. Atypical long-acting injectables, including paliperidone palmitate (PP), may increase adherence and improve symptoms. This study compared and assessed predictors of treatment patterns and symptom remission among schizophrenia patients treated with PP versus atypical oral antipsychotic therapy (OAT) in community behavioral health organizations (CBHOs)...
October 18, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29040230/serum-concentrations-of-paliperidone-after-administration-of-the-long-acting-injectable-formulation
#20
Arne Helland, Olav Spigset
BACKGROUND: The pharmacokinetics of long-acting intramuscular paliperidone in a naturalistic setting is not well documented. The objective of this study was to investigate the relationship between dose and serum concentrations of paliperidone using data from a routine therapeutic drug monitoring service. METHODS: Serum concentration measurements in 310 samples from 110 male and 75 female patients receiving depot injections of paliperidone were retrospectively retrieved from the therapeutic drug monitoring database...
December 2017: Therapeutic Drug Monitoring
keyword
keyword
32835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"